Stock Track | NovoCure Soars 13.08% in Pre-Market on Q1 Revenue Beat and Raised 2026 Guidance

Stock Track04-30

NovoCure's stock surged 13.08% in pre-market trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue outlook.

The oncology device maker reported Q1 revenue of $174.06 million, a 12% year-over-year increase that beat the consensus estimate of $167.87 million. The company also improved its gross margin to 78% from 75% in the prior year, driven by lower array costs and better utilization. Revenue growth was primarily fueled by active patient growth in European markets, with additional one-time benefits from Germany and France.

NovoCure raised its 2026 net revenue guidance to $690-$710 million from the previous range of $675-$705 million. The company also anticipates topline data from its Phase 3 TRIDENT trial in the second quarter of 2026, adding to positive investor sentiment. Wall Street analysts maintain a bullish stance, with a median 12-month price target of $25.00, representing significant upside potential from recent closing levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184505612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184505612","market":"nz","top_or_hot":-1,"title":"Stock Track | NovoCure Soars 13.08% in Pre-Market on Q1 Revenue Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>NovoCure's stock surged 13.08% in pre-market trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue outlook.</p><p>The oncology device maker reported Q1 revenue of $174.06 million, a 12% year-over-year increase that beat the consensus estimate of $167.87 million. The company also improved its gross margin to 78% from 75% in the prior year, driven by lower array costs and better utilization. Revenue growth was primarily fueled by active patient growth in European markets, with additional one-time benefits from Germany and France.</p><p>NovoCure raised its 2026 net revenue guidance to $690-$710 million from the previous range of $675-$705 million. The company also anticipates topline data from its Phase 3 TRIDENT trial in the second quarter of 2026, adding to positive investor sentiment. Wall Street analysts maintain a bullish stance, with a median 12-month price target of $25.00, representing significant upside potential from recent closing levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Soars 13.08% in Pre-Market on Q1 Revenue Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Soars 13.08% in Pre-Market on Q1 Revenue Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure's stock surged 13.08% in pre-market trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue outlook.</p><p>The oncology device maker reported Q1 revenue of $174.06 million, a 12% year-over-year increase that beat the consensus estimate of $167.87 million. The company also improved its gross margin to 78% from 75% in the prior year, driven by lower array costs and better utilization. Revenue growth was primarily fueled by active patient growth in European markets, with additional one-time benefits from Germany and France.</p><p>NovoCure raised its 2026 net revenue guidance to $690-$710 million from the previous range of $675-$705 million. The company also anticipates topline data from its Phase 3 TRIDENT trial in the second quarter of 2026, adding to positive investor sentiment. Wall Street analysts maintain a bullish stance, with a median 12-month price target of $25.00, representing significant upside potential from recent closing levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1184505612","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184505612","pubTimestamp":1777548628,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure's stock surged 13.08% in pre-market trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations and prompted the company to raise its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"个股追踪|NovoCure盘前飙升13.08%，Q1营收超预期并上调2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure's stock surged 13.08% in pre-market trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue outlook.The oncology device maker reported Q1 revenue of $174.06 million, a 12% year-over-year increase that beat the consensus estimate of $167.87 million. The company also improved its gross margin to 78% from 75% in the prior year, driven by lower array costs and better utilization. Revenue growth was primarily fueled by active patient growth in European markets, with additional one-time benefits from Germany and France.NovoCure raised its 2026 net revenue guidance to $690-$710 million from the previous range of $675-$705 million. The company also anticipates topline data from its Phase 3 TRIDENT trial in the second quarter of 2026, adding to positive investor sentiment. Wall Street analysts maintain a bullish stance, with a median 12-month price target of $25.00, representing significant upside potential from recent closing levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184505612","isCrawlerRequest":true}